Posted by Michael Wonder on 07 Apr 2021
FDA approves Althera’s Roszet (rosuvastatin and ezetimibe) tablets, a new oral therapy for powerful cholesterol reduction
31 March 2021 - Roszet is indicated for adults with primary non-familial hyperlipidaemia and homozygous familial hypercholesterolaemia.
Althera Pharmaceuticals today announced the FDA approval of Roszet (rosuvastatin and ezetimibe) tablets, as an adjunct to diet, for treatment of elevated low-density lipoprotein cholesterol in adult patients with primary non-familial hyperlipidaemia and in adults with homozygous familial hypercholesterolaemia.
